CN101167781A - Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof - Google Patents
Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof Download PDFInfo
- Publication number
- CN101167781A CN101167781A CNA2007101852352A CN200710185235A CN101167781A CN 101167781 A CN101167781 A CN 101167781A CN A2007101852352 A CNA2007101852352 A CN A2007101852352A CN 200710185235 A CN200710185235 A CN 200710185235A CN 101167781 A CN101167781 A CN 101167781A
- Authority
- CN
- China
- Prior art keywords
- folium ipomoea
- potato leaf
- chinese medicine
- extract
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a simple oral hypoglycemic traditional Chinese medicine of sweat potato leaf and process for preparation. Plant of sweat potato leaf is refluxed, extracted and concentrated through ethanol and ethanol extract is obtained. The ethanol extract after being absorbed through macroreticular absorbing resin is respectively eluted through distilled water, 10-20% ethanol and 40-60% ethanol, and the eluent liquid is concentrated and then is extracted through acetic ether. The extracting liquid is recycled and concentrated and extractum is obtained. The extractum is dried and the effective component of the sweat potato leaf--sweat potato leaf flavone is obtained. Tested by pharmacological experiment, sweat potato leaf flavone without toxic and side effects has the effect of reducing blood glucose and action time is lasting, thereby the invention can be used for curing type II diabetes and complication and provides a natural hypoglycemic medicament for non- insulin dependent diabetes mellitus (NIDDM).
Description
Technical field
The present invention relates to the medicine of a kind of treatment endocrine-metabolic system noninsulindependent diabetes (NIDDM, i.e. II type), and prevent the non-synthetic antidiabetic drug of its complication, it is feedstock production with the plant.
Background technology
Oneself becomes the Chronic Non-Communicable Diseases of the 3rd harm humans health diabetes after tumor, cardiovascular and cerebrovascular disease.World Health Organization (WHO) and IDF's data show that expecting whole world diabetics total number of persons in 2025 will reach 3.33 hundred million, and show along with crowd's average life prolongs according to 19 provinces and cities' diabetes findings of the survey that China announces, the increase of income and the change of life style (, psychentonia moving less, smoking drink etc.) as polyphagia, diabetes patient's sum will increase with the quantity in every year 100 ten thousand at least, and wherein NIDDM accounts for more than 90% of whole patients.
At present, oral antidiabetic drug commonly used is based on sulfonylurea (D860, glyburide, diamicron, Mei Bida, gliquidone, Gliguidone etc.), biguanides (phenformin, metformin etc.), Alpha-glucosidase inhibitor (acarbose) and euglycemic agent Western medicine such as (thiazolidinedioneses), these medicine life-time service or poor effect, or have than serious adverse, all can cause very big infringement to Liver and kidney, also can cause the generation of hypoglycemic reaction, even threat to life.Insulin is the specific medicament of treatment diabetes, but insulin causes biological activity to reduce for a long time with producing antibody, and dosage increases, and produces hyperinsulinemia, impels blood capillary generation pathological changes.And Chinese medicine is from the angle of differential diagnosis of diseases determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, and according to the disease characteristics of NIDDM, comprehensively regulating in addition on the integral level can make the appearance of NIDDM sx and delaying complications of diabetes.Therefore, screening and research antidiabetic drug are attracted attention by the countries in the world medical personnel from natural drug.
Radix Ipomoeae is traditional crops, extensively is planted in countries in the world.Folium Ipomoea is its side-product, studies show that, it has the enhance immunity ability, enhances metabolism, slow down aging, relieving constipation diuretic actions; for prevention of arterial sclerosis and various tumor; prevent cell carcinogenesis, vision protection etc. all have good health care function and medical effect.Flavone is one of effective ingredient of Folium Ipomoea, and the bioactivity research of Folium Ipomoea flavone treatment diabetes has not yet to see report.
Summary of the invention
The object of the present invention is to provide oral blood sugar lowering Chinese medicine of a kind of Folium Ipomoea folk prescription and preparation method thereof, the extract that the oral blood sugar lowering Chinese medicine of described Folium Ipomoea folk prescription is Folium Ipomoea, the extract that Folium Ipomoea obtains through suitable PROCESS FOR TREATMENT, can be the non-insulin-dependent diabetes mellitus patient a kind of nonsynthetic natural antidiabetic drug is provided, its definite functions, effect be lasting, have no side effect.
The preparation of Folium Ipomoea extract:
(1), adds the ethanol of 8～12 times of volumes 70%, 50～70 ℃ of reflux, extract, 3 times, merging filtrate with the Folium Ipomoea crushed after being dried;
(2) utilize the Rotary Evaporators concentrating under reduced pressure;
(3) D101 macroporous adsorptive resins on the diluent;
(4) use distilled water, 10～20% and 40～60% ethanol elutions respectively;
(5) use ethyl acetate extraction 3 times behind the concentrate eluant;
(6) vacuum drying obtains Folium Ipomoea extract.
The specific embodiment:
Below come further to set forth the beneficial effect of medicine of the present invention by experiment, these experiments have comprised the pharmacodynamic experiment and the clinical observation on the therapeutic effect experiment of medicine of the present invention.
Experiment is observed its influence to mouse blood sugar and blood fat by medicine of the present invention is carried out pharmaceutical research.
1. experiment material:
1.1 animal: cleaning level male Wistar rat, be 50-60 days ages, body weight 240-250g is provided by Concord Hospital's zooscopy.Free drinking public water supply, cleaning level animal feeding room, humiture is suitable, illumination 8-10h/d.
1.2 reagent: Folium Ipomoea, pick up from Hebei autumn, be accredited as Folium Ipomoea through plant expert contrast; Streptozotocin, U.S. Sigma company product; TC, TG, LDL-C, HDL-C, SOD, MDA, test kit are Nanjing and build up bio-engineering research institute product.
2. experimental technique
2.1 the structure of non-insulin-dependent diabetes mellitus rat model: the Wistar rat gives high sugared high caloric diet (10% sucrose, 10% Adeps Sus domestica, 1% cholesterol) to 4 weeks, (is dissolved in 0.1mol/L, PH4.2 citrate buffer solution with 0.25%STZ, matching while using) freely advances normal diet thereafter with 50mg/kg dosage disposable celiac injection 1.5ml., the drink tap water is surveyed fasting glucose behind the 72h.Blood glucose 〉=16.7mmol/l is considered as the diabetes rat of modeling success.
2.2 the preparation of Folium Ipomoea total flavones
(1), adds the ethanol of 10 times of volumes 70%, 60 ℃ of reflux, extract, 3 times, merging filtrate with the Folium Ipomoea crushed after being dried;
(2) utilize the Rotary Evaporators concentrating under reduced pressure;
(3) D101 macroporous adsorptive resins on the diluent;
(4) use distilled water, 20% and 60% ethanol elution respectively;
(5) use ethyl acetate extraction 3 times behind the concentrate eluant;
(6) vacuum drying obtains Folium Ipomoea extract.
2.3 experiment grouping
40 Wistar rats are divided into normal control group (8), modeling group (32) at random.Rat behind the Cheng Mo is divided into model control group, Folium Ipomoea flavone group (100mg/kg) and rosiglitazone group (3mg/kg) at random, each 8.Irritate 4 weeks of stomach.
2.4 blood sugar detection
Utilize kyoto, Japan blood glucose monitoring system and detection paper.
2.5 acute toxicological experiment
Adopt Cmax maximum volume (40mL/kg) disposable filling stomach kunming mice (19-21g), observe 7d continuously, record is tried the situations such as behavior, activity, food ration, body weight, feces and death of mice, and Si Wang mice is not put to death after 1 week and performs an autopsy on sb.
2.6 lipid determination
Behind the fasting 12h, get blood 2ml, 2000r/min immediately after the taking-up from eye socket, 4 ℃, centrifugal 10min obtains serum and is used for measuring serum cholesterol, triglyceride, low density lipoprotein, LDL, hdl level, utilize test kit, on the OLYMPUS biochemistry analyzer, measure.Survey Total antioxidant capacity and malonaldehyde (MDA) with spectrophotography; Measure superoxide dismutase (SOD) vigor with xanthine oxidase.The strict by specification of all operations carries out.
2.7 serum insulin (Ins) is measured: utilize euzymelinked immunosorbent assay (ELISA) to detect insulin, press the operation of test kit description.
2.8 the mensuration of carbohydrate tolerance
Carry out after the Folium Ipomoea flavone is handled the 15th day and the 30th day of oral glucose tolerance experiment.
The rat fasting is pressed the 2g/kg body weight and is irritated the stomach glucose after 2 hours, tail vein blood is measured 0min respectively, 30min, 60min, 90min and 120min blood glucose.
3 experimental results of the present invention:
3.1 acute toxinology experiment result
20 mice administration hair colors on the same day are smooth, and activity, diet, feces color and luster and quality are all normal, observe Folium Ipomoea flavone 24 h and irritate acute toxicity and the death condition that produces behind the stomach.To mouse stomach, make medicine reach Cmax (solution is very dense, is difficult to it be concentrated again), nothing death and other abnormal phenomena take place in 1 week.Perform an autopsy on sb after the execution, each main organs (heart, liver, spleen, lung, kidney) shows no obvious abnormalities change through perusal.Illustrate that the Folium Ipomoea flavone is actual nontoxic safer.
3.2 the Folium Ipomoea flavone is to the influence of NIDDM rat body weight
Before the modeling, each organizes rat body weight does not have significant difference.After the Folium Ipomoea flavone handled for 4 weeks, rat body weight was than the obvious reduction of model control group (P＜0.05). and the result shows that the Folium Ipomoea flavone has the effect that reduces the fat Mus body weight of diabetes.
Table 1 Folium Ipomoea flavone is to the influence of NIDDM rat body weight
| Group | Animal (only) | Body weight (g) | ||
| Before the modeling | Before FIBL handles | After FIBL handles | ||
| Normal control model contrast rosiglitazone (3mg/kg) FIBL (100mg/kg) | 8 8 8 8 | 248.67±5.58 248.6±5.49 248.66±5.7 248.63±5.56 | 307.21±9.69 341±9.71 ※ 343.25±8.8 ※ 342.31±8.0 ※ | 319.25±7.44 396.4±9.37 ※ 354.52±7.68 ※▲ 350.39±8.64 ※▲ |
Compare with the normal control group,
※P＜0.01; Compare with model control group,
▲P＜0.05
FIBL: Folium Ipomoea flavone; NIDDM: non-insulin-dependent diabetes mellitus
3.3 the Folium Ipomoea flavone is to the influence of NIDDM rat carbohydrate tolerance, FINS and ISI
After the Folium Ipomoea flavone handled for 4 weeks, tail vein blood was measured 0min respectively, 30min, blood glucose when 60min and 120min and insulin level.Model group rat blood sugar level 30min after giving glucose peaks, and is although after this blood sugar level begins to descend, still very high behind the 120min.Folium Ipomoea flavone processed group and model control group compare, and blood sugar level reduces behind the 60min, and when 120min, blood glucose is near normal level, and insulin sensitivity index significantly increases.Above result shows that the Folium Ipomoea flavone can improve non-insulin-dependent diabetes mellitus rat insulin resistance state and abnormal carbohydrate tolerance level.
Table 2 Folium Ipomoea flavone is to the influence of NIDDM rat oral glucose tolerance
| Group | Animal (only) | Blood sugar concentration (mmol/l) | |||
| 0min | 30min | 60min | 120min | ||
| Normal control model contrast rosiglitazone (3mg/kg) FIBL (100mg/kg) | 8 8 8 8 | 4.29±0.53 6.10±0.87 ★ 4.87±0.64 ※▲ 4.78±0.66 ※▲ | 8.10±0.84 17.05±1.23 ★10.71±1.53 ※▲11.87±1.71 ※▲ | 7.26±0.89 15.64±0.89 ★ 9.10±0.79 ※■ 10.11±0.89 ※▲ | 5.91±0.71 13.45±1.56 ★ 7.38±0.54 ■ 6.36±0.52 ※■ |
Compare with the normal control group,
※P＜0.05,
★P＜0.01; Compare with model control group,
▲P＜0.05,
■P＜0.01
FIBL: Folium Ipomoea flavone; NIDDM: non-insulin-dependent diabetes mellitus
Table 3 Folium Ipomoea flavone is to the influence of NIDDM rat FINS and ISI
| Group | Animal (only) | Before FIBL handles | After FIBL handles | ||
| FINS(mIU/L) | ISI | FINS(mIU/L) | ISI | ||
| Normal control model contrast rosiglitazone (3mg/kg) FIBL (100mg/kg) | 8 8 8 8 | 18.29±4.08 31.23±3.25 ※ 30.55±3.79 ※ 30.36±2.61 ※ | -4.45±0.21 -5.26±0.16 ※ -5.18±0.13 ※ -5.23±0.16 ※ | 18.97±3.01 29.65±3.21 ※ 23.14±2.12 ※■ 24.25±2.28 ※▲ | -4.46±0.24 -5.23±0.17 ※ -4.72±0.11 ■ -4.93±0.14 ▲ |
Compare with the normal control group,,
※P＜0.01; Compare with model control group,
▲P＜0.05,
■P＜0.01
FIBL: Folium Ipomoea flavone; ISI: insulin sensitivity index; FINS is serum insulin on an empty stomach; NIDDM: non-insulin-dependent diabetes mellitus
3.4 the Folium Ipomoea flavone is to the influence of NIDDM rat fat
After the Folium Ipomoea flavone handled for 4 weeks, compare with model control group, hdl concentration increases to some extent, but does not have significant difference (P＞0.05); T-CHOL, triglyceride and low-density lipoprotein white level significantly reduce, and reduce by 26.48% (P＜0.01), 14.07% (P＜0.01) and 40.82% (P＜0.01) respectively.The above results shows that the Folium Ipomoea flavone has tangible effect for reducing fat to the non-insulin-dependent diabetes mellitus rat.
Table 4 Folium Ipomoea flavone is to NIDDM rat TC, TG, the influence of HDL-C and LDL-C level
| Group | Animal (only) | TC (mmol/l) | TG (mmol/l) | HDL-C (mmol/l) | LDL-C (mmol/l) |
| Normal control model contrast rosiglitazone (3mg/kg) FIBL (100mg/kg) | 8 8 8 8 | 2.02±0.17 2.87±0.16 ▲ 2.09±0.19 ※■ 2.11±0.21 ※■ | 0.88±0.15 1.21±0.19 ▲ 1.04±0.14 ※■ 1.04±0.08 ※■ | 0.95±0.24 0.78±0.18 0.87±0.20 0.83±0.23 | 0.51±0.22 0.98±0.23 ▲ 0.56±0.09 ■ 0.58±0.13 ■ |
Compare with the normal control group,
※P＜0.05,
▲P＜0.01; Compare with model control group,
■P＜0.01
FIBL: Folium Ipomoea flavone; TC: cholesterol; TG: triglyceride; HDLC: high density lipoprotein; LDL-C: low density lipoprotein, LDL; NIDDM: non-insulin-dependent diabetes mellitus
3.5 the Folium Ipomoea flavone is to the influence of MDDM rat SOD and MDA
The Folium Ipomoea flavone handled for 4 weeks, and with the model control group ratio, SOD content increases by 17.67% (P＜0.01), and MDA content significantly reduces by 38.69% (P＜0.01).This result shows that the Folium Ipomoea flavone has good non-oxidizability.
Table 5 Folium Ipomoea flavone is to the influence of NIDDM rat SOD and MDA level
| Group | Animal (only) | SOD(Nu/ml) | MDA(nmol/ml) |
| Normal control model contrast rosiglitazone (3mg/kg) FIBL (100mg/kg) | 8 8 8 8 | 154.60±13.09 119.21±8.56 ▲ 143.01±11.78 ※■ 140.27±12.67 ※■ | 5.61±1.73 9.28±1.67 ▲ 5.68±2.19 ※■ 5.69±2.18 ※■ |
Compare with the normal control group,
※P＜0.05,
▲P＜0.01; Compare with model control group,
■P＜0.01
FIBL: Folium Ipomoea flavone; SOD: superoxide dismutase; MDA: malonaldehyde; NIDDM: non-insulin-dependent diabetes mellitus
4. discuss
This zoopery is reliable through the repeated experiments proving effect, and after this animal drug withdrawal three months simultaneously, survey blood glucose again, blood glucose still maintains normal level, and the mental status is fine.Non-insulin-dependent diabetes mellitus rat model blood glucose, blood fat and level of lipid raise in this research, and Folium Ipomoea flavone processed group blood glucose, blood fat and level of lipid reduce, and antioxidase content increases.Illustrate that this medicine can be used for the treatment of non-insulin-dependent diabetes mellitus.
In addition, the present invention can be prepared into capsule, powder, granule or tablet according to practical situation clinical practice is provided, and can add appropriate amount of starch or other adjuvant as additive when the above-mentioned preparation of preparation.
Claims (4)
1. Orally-administered hypoglycemic sweet potato leaf single prescription Chinese medicine is characterized in that: the extract that the oral blood sugar lowering Chinese medicine of described folk prescription is Folium Ipomoea, and the extract of described Folium Ipomoea contains Folium Ipomoea total flavones composition; The said extracted thing has new medical usages such as blood sugar lowering, blood fat reducing.
2. method for preparing the oral blood sugar lowering Chinese medicine of the described Folium Ipomoea folk prescription of claim 1, it is characterized in that: the preparation of Folium Ipomoea extract is:
(1), adds the ethanol of 8～12 times of volumes 70%, 50～70 ℃ of reflux, extract, 3 times, merging filtrate with the Folium Ipomoea crushed after being dried;
(2) utilize the Rotary Evaporators concentrating under reduced pressure;
(3) D101 macroporous adsorptive resins on the diluent;
(4) use distilled water, 10～20% and 40～60% ethanol elutions respectively;
(5) use ethyl acetate extraction 3 times behind the concentrate eluant;
(6) vacuum drying, Folium Ipomoea extract.
3. the method for Orally-administered hypoglycemic sweet potato leaf single prescription Chinese medicine according to claim 2 is characterized in that: the said extracted thing can be prepared into capsule, powder, granule or tablet in clinical practice.
4. the method for Orally-administered hypoglycemic sweet potato leaf single prescription Chinese medicine according to claim 3 is characterized in that: can add appropriate amount of starch or other adjuvant as additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101852352A CN101167781A (en) | 2007-11-09 | 2007-11-09 | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101852352A CN101167781A (en) | 2007-11-09 | 2007-11-09 | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101167781A true CN101167781A (en) | 2008-04-30 |
Family
ID=39388628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101852352A Pending CN101167781A (en) | 2007-11-09 | 2007-11-09 | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101167781A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697058A (en) * | 2012-06-13 | 2012-10-03 | 山东省农业科学院农产品研究所 | Preparation method of sweet potato stem-leaf extract |
| CN104366313A (en) * | 2013-08-15 | 2015-02-25 | 珠海市红旌发展有限公司 | Sweet potato leaf chewable tablet |
| CN105708882A (en) * | 2014-12-05 | 2016-06-29 | 广西大学 | Extraction process of sweet potato fol. flavone |
| CN110179117A (en) * | 2019-07-15 | 2019-08-30 | 青岛瑞思德生物科技有限公司 | A kind of hypoglycemic particle electuary and preparation method thereof |
| CN111109472A (en) * | 2020-01-22 | 2020-05-08 | 海南晨海水产有限公司 | Compound feed for grouper larvae and juveniles and preparation method thereof |
-
2007
- 2007-11-09 CN CNA2007101852352A patent/CN101167781A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102697058A (en) * | 2012-06-13 | 2012-10-03 | 山东省农业科学院农产品研究所 | Preparation method of sweet potato stem-leaf extract |
| CN104366313A (en) * | 2013-08-15 | 2015-02-25 | 珠海市红旌发展有限公司 | Sweet potato leaf chewable tablet |
| CN105708882A (en) * | 2014-12-05 | 2016-06-29 | 广西大学 | Extraction process of sweet potato fol. flavone |
| CN110179117A (en) * | 2019-07-15 | 2019-08-30 | 青岛瑞思德生物科技有限公司 | A kind of hypoglycemic particle electuary and preparation method thereof |
| CN111109472A (en) * | 2020-01-22 | 2020-05-08 | 海南晨海水产有限公司 | Compound feed for grouper larvae and juveniles and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102274244B (en) | Cassia bark polyphenol extract and preparation method and application thereof | |
| CN106606529A (en) | Composition with auxiliary blood sugar reduction efficacy, and preparation method and application thereof | |
| CN103417749A (en) | Preparing method of herba violae extract and application of herba violae extract in hypoglycemic agents | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN101167781A (en) | Orally-administered hypoglycemic sweet potato leaf single prescription traditional Chinese medicine and preparation method thereof | |
| CN101618096B (en) | Madder extract and preparation method and application thereof | |
| CN101347495B (en) | Preparation of Glabridin dispersible tablets and use of the tablets in reducing blood sugar as medicament active composition | |
| CN102224924B (en) | Sea cucumber saponin-containing composition and its application in foods and drugs | |
| CN101336974B (en) | Traditional Chinese medicine for reducing blood sugar and regulating lipid with overall regulation of body metabolism and preparation method thereof | |
| CN111450136B (en) | Oyster and kudzu root composite particles and preparation method thereof | |
| CN101028320B (en) | Vegetable medicinal composition with hypoglycemic and hypolipidemic functions and its making method | |
| KR20040032920A (en) | Fermentation product of cyptoporus volvatus and its preparation method and use | |
| CN101283717B (en) | Flower silk leaf bagged tea and its preparation method | |
| CN102697781A (en) | Application of trigonelline in preparation of medicament for preventing and treating diabetes and complication thereof | |
| CN101849950A (en) | Application of rotundic acid in preparing blood lipid regulating medicines | |
| CN103585192A (en) | Preparation method and application of Aleuritopteris argentea Fee extract | |
| CN101336965B (en) | Chinese prepared medicine for improving sugar tolerance and reducing blood sugar and preparation method thereof | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN106214787B (en) | A kind of Chinese medicine composition for treating diabetes and preparation method thereof and purposes | |
| CN106265717B (en) | Application of the dicliptera chinensis polysaccharide in preparing prevention diabetes medicament or health products | |
| CN101884723B (en) | Anemarrhena and goldthread composition preparation used for treating diabetes and preparation method thereof | |
| CN1618335A (en) | Health-care food with assistant functions of decreasing blood-sugar and blood-fat, and its prepn. method | |
| CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN102225082B (en) | Medicament for preventing and treating diabetes and complications thereof and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20080430 |